BMRN News and Press, BioMarin Pharmaceutical Inc. From 05/17/24

2024-05-17 05:00:04 ET Jack Allen from Robert W. Baird issued a price target of $72.00 for BMRN on 2024-05-17 03:08:00. The adjusted price target was set to $72.00. At the time of the announcement, BMRN was trading at $76.97. The overall price target consensus is at $115...

2024-05-16 04:33:48 ET Third Point,  the hedge fund run by Dan Loeb, increased its position in Amazon.com ( NASDAQ: AMZN ) by 900K to 5.1M shares and Intercontinental Exchange ( NYSE: ICE ) by 300K to 1M shares in Q1.... Read the full article on Seeking Alpha ...

2024-05-15 11:24:22 ET More on Brinker, Leggett & Platt, etc. Leggett & Platt, Incorporated (LEG) Q1 2024 Earnings Call Transcript Leggett & Platt Cuts Its Dividend: Signs Of An Existential Threat? Leggett & Platt, Incorporated 2024 Q1 - Results - Ear...

2024-05-15 09:55:08 ET Summary BioMarin's 1Q24 revenue was $649 million, with a 9% YoY increase, but uncertainty around the commercial prospects of Roctavian has dampened optimism. The company's core drug portfolio performed as expected, with some drugs exceeding consensus expecta...

2024-05-14 17:49:43 ET More on BioMarin Pharmaceutical BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth Evercore says biotech ‘winter is finally thawing’ BioMarin touts new data on Voxzogo for additional indications BioMarin Pharmaceu...

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $113.00 for BMRN on 2024-05-13 16:10:00. The adjusted price target was set to $113.00. At the time of the announcement, BMRN was trading at $80.5. The overall price target consensus is at $114...

2024-05-09 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV PR Newswire SAN RAFAEL, Calif. , May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that ...

2024-05-08 06:55:36 ET Summary Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a b...